Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldoxorubicin - NantCell

Drug Profile

Aldoxorubicin - NantCell

Alternative Names: Aldoxorubicin hydrochloride; DOXO-EMCH; Doxorubicin-6-maleimidocaproyl hydrazone; INNO-206; Tumour-targeted doxorubicin conjugate - CytRx Corporation

Latest Information Update: 29 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KTB Tumorforschungs
  • Developer CytRx Corporation; NantCell
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Hydrazines; Maleimides; Pyrroles; Small molecules
  • Mechanism of Action DNA intercalators; Reactive oxygen species stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Glioblastoma; Soft tissue sarcoma; Pancreatic cancer; Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Soft tissue sarcoma
  • Phase II Glioblastoma; Kaposi's sarcoma; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Chondrosarcoma; Colorectal cancer; Osteosarcoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 20 Jun 2018 NantKwest plans the QUILT-3.088 phase II trial for Pancreatic Cancer (Metastatic disease) in USA , (NCT03563144)
  • 07 Jun 2018 Pooled efficacy and adverse events data from a phase III and phase II trial in Soft tissue sarcoma released by CytRx
  • 25 May 2018 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03563157)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top